Skip to main content
OpenTrials
Completed

NCT Number: NCT02265588

Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).

The presented study aims to reduce symptoms of depression and anxiety in adolescents with inflammatory bowel disease and increased symptoms of anxiety and depression by using the disease specific CBT program (PASCET-PI)in order to improve quality of life and to improve the clinical course of disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Erasmus Medical Center

Rotterdam, Nederland, 3015CN, Netherlands

About this study

  • Objective: The primary objective is to determine the efficacy of a disease specific cognitive behavioral therapy program in adolescents with IBD and increased symptoms of depression or anxiety on reducing symptoms of depression. Secondary objectives are to assess the effect of the CBT program on a) the clinical course of disease b) reducing symptoms of anxiety, and c) improving quality of life. We also aim to identify psychosocial and medical factors that predict or moderate the treatment response to CBT in adolescent with IBD.
  • Study design: The presented study is a multicenter randomized controlled trial (RCT), involving CBT versus care as usual (CAU), in young IBD patients with increased symptoms of self-reported depression or anxiety. There will be three follow-up moments, after 3 months or after the intervention and after 6 and 12 months.
  • Study population: Patients with IBD between 10-25 years and increased symptoms of depression or anxiety. We aim to include 100 patients, from which 50 patients will be randomized to the treatment condition (CBT and CAU) and 50 to the control group (CAU).
  • Intervention: A disease specific CBT program called PASCET-PI. The control group (CAU),will receive routine medical treatment (thus no additional psychosocial intervention) and will maintain their regular follow up visits at the gastroenterologist every 3 months.
  • Main study endpoints: Main outcome is reduction in symptoms of depression. Important secondary outcomes are the presence of clinical relapse and reduction of symptoms of anxiety. Other secondary outcomes, amongst others, are IBD activity scores, quality of life, psychosocial functioning, and adherence to medical treatment.
  • Nature and extent of the burden and risks associated with participation, benefit and group relatedness: At first, patients with IBD 10 -25 years of age will be screened for symptoms of depression and anxiety at T1. Patients with increased symptoms of self-reported depression or anxiety (scoring above an age and gender specific cut-off score for increased depressive or anxiety symptoms) are asked to participate in the RCT. For all included patients, 4 study visits will take place, these will be combined with regular checkup visits at the gastroenterologist. Questionnaires will need to be filled in online, taking approximately 1.5 hour per assessment for patients and approximately 1 hour per assessment for parents. At baseline a psychiatric assessment interview will be executed by an independent research clinical psychologist by phone (20 minutes). The same research clinical psychologist will conduct a short psychiatric assessment interview at the follow up visits 10minutes). At baseline and after 3 months blood samples (when patients undergo routine venous punctures) will be drawn.

For patients in the CBT group, 13 sessions (6 outpatient sessions, 7 by phone) and three parental sessions will take place in a hospital close to their home. Our study population consists of adolescents and young adults with IBD, as this is a specific group with high reported symptoms of depression and anxiety, therefore they will most likely benefit from the intervention. The risks associated with participation can be considered negligible and the burden minimal. For the time investment of completing the questionnaires participants will receive an incentive of 25 euro after the final assessment, which will be communicated at the start.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients between 10-25 years with diagnosed IBD
  • Informed consent or assent by patients and (if necessary) parents

Exclusion criteria

  • IBD patients with parental report of mental retardation
  • IBD patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety
  • No mastery of the Dutch language
  • IBD patients with diagnosed: Bipolar disorder, Schizophrenia/psychotic disorder, Autism spectrum disorders, Obsessive-compulsive disorder, Posttraumatic stress disorder/Acute stress disorder, or Substance use disorder
  • Physician reported substance abuse (alcohol, drugs) in the past month
  • Clinician reported Selective mutism
  • IBD patients already participating in an (psychological of psychopharmacological) intervention study
  • IBD patients who received 8 sessions of manualized cognitive behavioral therapy last year
  • current psychological treatment

Treatment and study plan

Cognitive behavioral therapy

Behavioral

A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.

Primary outcomes

  1. Reduction in symptoms of depression (change from baseline)

    Time frame: 12 weeks and 52 weeks

    Measured by the Child Depression Inventory (CDI (10-17 years), Beck Depression Inventory (BDI; 18-25 years) and severity rating (interview): the Children's Depression Rating Scale (CDRS;10-12 years) and Adolescent Depression Rating Scale(ADRS;13-20 years), HAM-D: Hamilton Depression Rating Scale (21-25 year)

Secondary outcomes

  1. Reduction in symptoms of anxiety (change from baseline)

    Time frame: 12 weeks and 52 weeks

    Measured by SCARED-NL: Screen for Anxiety Related Emotional Disorders (10-20 years), Hospital Anxiety and Depression Scale (HADS; 21-25 year) and severity rating by Pediatrix Anxiety Rating Scale (PARS) (10-20 years) ,Hamilton Anxiety Rating (HAM-A)(21-25 year)

  2. General Quality of Life

    Time frame: 12 weeks and 52 weeks

    Assessed by the Child Health Related Quality of Life (TACQOL) (10-15 years) Adult Health Related Quality of Life (TAAQOL, 16-25 years)

  3. Social Skills

    Time frame: 12 weeks

    Assessed by Social Skills Rating System (SSRS) (10-20years) Novotni SSC: Social Skills Checklist (21-25 year)

  4. Social competence

    Time frame: 12 weeks

    Assessed by Youth Self Report (YSR) / Adult Self Report (ASR)

  5. Disease specific quality of life

    Time frame: 12 weeks and 52 weeks

    Assessed by the IMPACT-III-NL (10-20years) IBDQ: Inflammatory Bowel Disease Questionnaire (21-25 year)

  6. Disease Activity

    Time frame: 52 weeks

    Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) (10-20 years) Pediatric Crohn's Disease Activity Index (PCDAI) (10-20 years) CDAI: Crohn's Disease Activity Index (21-25 years) Partial Mayo Score (21-25 years) Physician Global Assessment (PGA)

  7. Clinical relapse (number of flares)

    Time frame: 52 weeks

    10-20 Years: Relapse for CD is defined as PCDAI>30 or an increase of>15 points and intensification of medical treatment.

    Relapse for UC is defined as PUCAI > 34 or an increase of ≥20 points for UC and intensification of medical treatment.

    21-25 years: Partial Mayo score of 3 or higher with intensification of medical treatment Or CDAI≥ 150 and an increase in baseline CDAI score of ≥ 70 points and intensification of medical treatment

  8. Maintaining remission

    Time frame: 52 weeks

    Remission is defined as PCDAI < 10 for CD and PUCAI < 10 for UC. CDAI < 150 and Mayo score ≤2 with no individual subscore > 1

  9. Medication Usage (change from baseline)

    Time frame: 52 weeks

    Type and dosage of medication

  10. Necessity of surgical intervention

    Time frame: 52 weeks

    Description of type and extent of surgical intervention

  11. Adherence to therapy (change from baseline)

    Time frame: 52 weeks

    Assessed by the Morisky Medical Adherence Scale (MASS-8)

  12. Health care utilization (change from baseline)

    Time frame: 52 weeks

    Assessed by standardized items derived from the questionnaires and Report of the treating physician.

  13. Inflammatory markers

    Time frame: baseline and 12, 24 and 52 weeks

    Inflammatory markers will be measured at all time points (baseline and after 3,6,12 months) Inflammatory markers like BSE, CRP, faecal calprotectin

Other outcomes

  1. Disease perception (change from baseline)

    Time frame: 12 weeks

    Assesses by the Brief Illness Perceptions Questionnaire (B-IPQ)

  2. Cognitive coping styles (change from baseline)

    Time frame: 12 weeks

    Assesses by the Cognitive Emotion Regulation Questionnaire (CERQ)

  3. Quality of sleep (change from baseline)

    Time frame: 12 weeks

    Assesses by the Sleep Self-Report (SSR) (10-20 years) PSQI: Pittsburgh Sleep Quality Index (21-25 year)

  4. Demographic factors

    Time frame: 12 weeks

    Assesses by the Rotterdam's quality of life interview

  5. Parental anxiety and depression

    Time frame: 12 weeks

    Assesses by the Depression, Anxiety and Stress Scale (DASS-21)

  6. Life Events

    Time frame: 12 weeks

    Assesses by the Life events questionnaire from CERQ

  7. Family Functioning (change from baseline)

    Time frame: 12 weeks

    Assesses by the Family Assessment Device (FAD)

  8. Disease phenotypes

    Time frame: 52 weeks

    Assessed by the Paris Classification

  9. Treatment Strategy

    Time frame: 52 weeks

    The treatment strategy, type and dosage of medication will be extracted from the medical file and report of the treating physician.

  10. White blood cell RNA expression profiles (change from baseline)

    Time frame: 12 weeks

    Assessing immune status is done by analyzing gene expression profiles in peripheral blood leukocytes. This will be performed

  11. Immunological activity in peripheral blood mononuclear cells (PBMC)

    Time frame: 12 weeks

    A blood sample will be taken in all patients included within the Erasmus MC for determination of responsiveness of peripheral blood lymphocytes before and directly after the intervention

  12. Irritable bowel syndrome -like symptoms

    Time frame: 12 months

    Assessed by the ROME III diagnostic criteria for IBS in pediatric IBD patients

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Collaborators

  • Albert Schweitzer Hospital
  • Amphia Hospital
  • Haga Hospital
  • Leiden University Medical Center
  • Maasstad Hospital
  • Reinier de Graaf Groep

Registry information

Official study title

Reducing Symptoms of Depression and Anxiety in Adolescents With Inflammatory Bowel Disease in Order to Improve Quality of Life and the Clinical Course of Disease.

Acronym: HAPPY-IBD

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Oct 16, 2014
Registry last updated
Jul 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.